measure the utility of rituximab as first-line therapy for BP.
From 2010 to 2012 we performed a retrospective casecontrol study in a referral centre in Taiwan, including patients with the generalized form of BP requiring systemic treatment. Diagnosis of BP was based on typical clinical presentations, characteristic histopathological findings, and the presence of autoantibodies on direct and/or indirect immunofluorescence studies. In the first-line combination therapy group (group R), the regimen included four weekly infusions of 500 mg rituximab (MabThera TM ; Roche, Basel, Switzerland), and corticosteroids, with a starting dose of prednisolone of 0Á5 mg kg À1 daily ( Table 1 ). The dose of corticosteroids was tapered rapidly after disease was controlled. Each dose lasted for 3-4 weeks, with a total duration of < 6 months. As a comparison (group C), to ensure the similarity of severity, we included patients from the same period receiving a similar starting dose of prednisolone for at least 6 months (Table 1) . We excluded those with localized or mild disease, which could be controlled by topical treatment or a short course of systemic treatment. All patients were followed for 1 year or until death. In both groups, the average age, BP Disease Area Index values, 4 blood eosinophil counts and the presence of comorbidities were similar (Table 2 ). More than 90% of patients in group R achieved complete remission (CR), a status of no established or new lesions for at least 2 months, 4 which was significantly higher than in group C (P = 0Á02). Notably, eight of the patients achieving CR in group R achieved CR off therapy (CRoff). Of these eight patients, four maintained CRoff during the follow-up period of > 2 years. The other four experienced disease recurrence. Nevertheless, relapses in these cases were mild and easily controlled. The mean duration of CRoff in these four patients was 27 weeks (range 22-35 weeks). The risk of infection was slightly lower in group R than in group C (31% vs. 53%), but it was not statistically significant (P = 0Á22). Urinary tract infection and pneumonia were the leading infections in groups R and C, respectively. The 1-year mortality rate of group R was much lower than that of group C (15% vs. 37%), but it was not significantly different (P = 0Á18).
To date, only anecdotal reports have mentioned the use of rituximab in BP. 5, 6 Our study is the first to use rituximab as a firstline treatment in BP, and demonstrates a significantly better rate of CR than conventional treatment. A recent review article reports infection and mortality rates of around 20%, and suggests that careful and close monitoring may be neccessary.
7
These results are consistent with ours. Indeed, infections are the most important cause of mortality in our study, as also reported in another study. 8 Nevertheless, our study provides a comparison and shows that first-line combination therapy has similar or even lower rates of infection and mortality than conventional treatment. This might result from rapid tapering and withdrawing systemic corticosteroids in group R (Table 2) , as a lower dose of systemic corticosteroids may reduce the rate of mortality. 9 In conclusion, we demonstrate that first-line combination therapy with rituximab and corticosteroids is effective and relatively safe for moderate-to-severe BP. A large prospective study is needed to confirm our observations.
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1 Characteristic signs present at birth or in the first weeks of life, namely strikingly unilateral ichthyosiform skin lesions with a sharp midline demarcation, and ipsilateral limb defects (ranging from hypoplasia of the phalanges to absence of the entire extremity). 1, 3 The face is usually spared. The central nervous system, lungs, heart and kidneys can also be involved. 2 We report a case of CHILD syndrome without the characteristic hemidysplasia.
A 7-year-old girl was referred to our department for evaluation of areas of persistently inflamed and hyperkeratotic skin. She was born at 35 weeks of gestation by caesarean section for breech presentation, without gross limb defects. Her medical history revealed a radiological diagnosis of spinal chondrodysplasia punctata with atlantoaxial subluxation and intermittent spinal compression, bilateral hip subluxation, severe neurodevelopmental delay, chronic lung disease requiring tracheostomy and night-time ventilation, gastro-oesophageal reflux and gastrostomy feeding. Brain magnetic resonance imaging had revealed general loss of white matter bulk but with no asymmetry. The skin lesions had been present from birth, and persistent symptoms were recurrent painful fissuring and pruritus. Cutaneous examination revealed inflammatory ichthyotic lesions along the lines of Blaschko on both upper limbs (right more than left), in the right groin, and diffusely on both cheeks. In addition, there were areas of persistent nonscarring alopecia bilaterally on the scalp, one circular and well circumscribed, and the other more diffuse, with no evidence of trichotillomania. Dysmorphic facial features included deep-set eyes and epicanthic folds. Importantly, and compatible with previous reports, 4 the patient's mother had similar but much milder linear hyperkeratotic skin lesions affecting the right arm and hand, but was otherwise unaffected (Fig. 1 ).
Skin biopsy of affected skin from the patient showed features compatible with ichthyosiform dermatosis: acanthosis and extension of rete pegs of the epidermis, marked parakeratotic scaling with loss of the granular layer, occasional clusters of neutrophils, and perivascular and dermal lymphohistiocytic infiltrates (Fig. 2) , but without the characteristic verruciform xanthoma of CHILD syndrome. Array comparative genomic hybridization analysis of peripheral blood leucocyte DNA was normal, excluding large copy number changes (resolution 150 kb). Sanger sequencing revealed a novel germline heterozygous microdeletion inducing a frameshift and premature stop codon at position 119 of a total translated length of 373 amino acids in NSDHL (c.357_358del, p.Arg119Serfs*1d), predicted damaging in silico. This mutation is compatible with the previously reported disease-causing mutations in classical CHILD syndrome, 1 and on the basis of current knowledge confirmed a genetic diagnosis of CHILD syndrome in both the patient and her mother. No other changes in the gene were identified. Previously reported mutations have principally been heterozygous nonsense or missense point mutations, and large heterozygous deletions have been described. 3, 5 This novel microdeletion would be predicted to cause loss of function by truncating the protein before the catalytic site of the gene product. Traditionally, management of skin lesions in CHILD syndrome has been difficult; however, Paller et al. recently reported an innovative and highly successful topical therapy in two patients -co-application of cholesterol 2% and lovastatin 2% -based on the role of NSDHL in cholesterol metabolism. 6 These results have been replicated in three further reports of patients using co-application of cholesterol 2% and simvastatin 2%, 7 and has been successfully trialled in our patient, with complete resolution of erythema and hyperkeratosis in the treated groin area. Two other conditions are interesting to consider in this atypical case (Table 1) . Firstly, the recently described allelic disorder CK syndrome (MIM #300831), caused by milder mutations in NSDHL, is characterized by cortical malformations, typical facial features, asthenic body habitus and no described cutaneous phenotype. Our patient does not exhibit typical features of this syndrome. Secondly, Conradi-Hunermann-Happle (CHH) syndrome is an X-linked dominant disorder caused by mutations in the emopamil-binding protein gene (EBP), which governs the next step in the cholesterol biosynthetic pathway after NSDHL. The presence of chondroplasia punctata, intellectual disability and alopecia have all been described in CHH syndrome; however, disproportionate skeletal growth, growth deficiency, characteristic linear/whorled pigmentary lesions and cataracts were lacking in our patient. Furthermore, the histological features in this case support a diagnosis of CHILD syndrome and exclude a diagnosis of CHH. A clear bilateral presentation in CHILD syndrome has been reported rarely before, once with characteristic skin lesions affecting the body folds in a near-symmetrical distribution, associated with a novel missense mutation in NSDHL, 8, 9 twice with contralateral linear skin lesions, 1 once with bilateral, almost symmetrical, linear lesions on the extremities. 10 Our case confirms this bilateral cutaneous presentation, emphasizes the significant inter-and intrafamilial variation, and extends the noncutaneous phenotype of CHILD syndrome.
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